ArticleFrontiers in microbiology2018
Amikacin Liposome Inhalation Suspension (ALIS) Penetrates Non-tuberculous Mycobacterial Biofilms and Enhances Amikacin Uptake Into Macrophages.
Article in Frontiers in microbiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
88 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Precision nanomedicine for pulmonary diseases: from molecular targeting to clinical translation.Signal transduction and targeted therapy · 2026Review
- Nanotechnology-Enabled Strategies to Overcome Antibiotic Resistance in Respiratory Infections: Mechanisms, Platforms, and Translational Challenges.Biomedicines · 2026Review
- Pulmonary Drug Delivery in the Era of Nanomedicine: From Biological Barriers to Artificial Intelligence-Driven Optimization.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Deferoxamine Exhibits Antimicrobial and Immunomodulatory Activity AgainstInternational journal of molecular sciences · 2026Article
- Phenotype-Guided Nanotherapeutic Strategies for Carbapenem-ResistantPharmaceutics · 2026Review
- Clinical factors and practical strategies to optimize amikacin liposome inhalation suspension therapy in refractory Mycobacterium avium complex pulmonary disease.BMC pulmonary medicine · 2026Article
- 6-methylflavone exerts selective antimycobacterial activity with membrane energetics disruption and demonstrates therapeutic potential againstMicrobiology spectrum · 2026Article
- Liposomal antimicrobials in the fight against bacterial and fungal pathogens: Clinical successes and development challenges.International journal of pharmaceutics: X · 2026Review
- Article
- Mucopenetrative Lipid-Polymer nanoparticles show Potent Anti-Inflammatory activity in a human Lung-on-Chip model.International journal of pharmaceutics · 2026Article
- Lipid accumulation and interstitial lung disease associated with amikacin liposomal inhalation suspension in patients with Mycobacterium avium complex lung disease: a single-center retrospective cohort study.BMC pulmonary medicine · 2026Article
- Enhancement of tobramycin and amikacin activities by co-encapsulation in liposomal-thymoquinone formulation: antibacterial, antibiofilm, and cytocompatibility study.Therapeutic delivery · 2026Article
- Report on Successful Treatment of Refractory MAC 2 Lung Disease in Two Elderly Patients with Inhaled Liposomal Amikacin (ALIS) at Half the Standard Dose.Diseases (Basel, Switzerland) · 2026Article
- Inhalable Nanosystems for Bacterial Respiratory Infections: Addressing Pulmonary Barriers and Biofilm-Associated Challenges.International journal of nanomedicine · 2026Review
- Amikacin Liposomal Inhalation Suspension: Advances in Application Against RefractoryInfection and drug resistance · 2026Review
- Mycobacterium florentinum pulmonary disease: a case report and review of the literature.BMC infectious diseases · 2025Review
- Article
- Improved Encapsulation and Potential of Liposomal Tosufloxacin via Inclusion in Cyclodextrin.AAPS PharmSciTech · 2025Article
- Oral β-lactam combinations are effectiveMicrobiology spectrum · 2025Article
28 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-tuberculous mycobacteria (NTM) cause pulmonary infections in patients with structural lung damage, impaired immunity, or other risk factors. Delivering antibiotics to the sites of these infections is a major hurdle of therapy because pulmonary NTM infections can persist in biofilms or as intracellular infections within macrophages. Inhaled treatments can improve antibiotic delivery into the lungs, but efficient nebulization delivery, distribution throughout the lungs, and penetration into biofilms and macrophages are considerable challenges for this approach. Therefore, we developed amikacin liposome inhalation suspension (ALIS) to overcome these challenges. Nebulization of ALIS has been shown to provide particles within the respirable size range that distribute to both central and peripheral lung compartments in humans. The
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.